Company profile for Akebia Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We were founded in 2007 to discover and develop therapeutic solutions leveraging the potential of hypoxia inducible factor—or HIF—biology. We believe HIF-Prolyl Hydroxylase (HIF-PH) inhibition could represent an approach to treating certain conditions where there is unmet need. Our objective is to develop and commercialize these products, starting with our lead compound, vadadustat, an investigational product being studied...
We were founded in 2007 to discover and develop therapeutic solutions leveraging the potential of hypoxia inducible factor—or HIF—biology. We believe HIF-Prolyl Hydroxylase (HIF-PH) inhibition could represent an approach to treating certain conditions where there is unmet need. Our objective is to develop and commercialize these products, starting with our lead compound, vadadustat, an investigational product being studied in patients with anemia due to chronic kidney disease (CKD).

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
245 First Street, Suite 1400 Cambridge, MA 02142
Telephone
Telephone
+1 617-871-2098
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/01/3197426/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/12/01/3196841/37519/en/Akebia-Announces-Establishment-of-Rare-Kidney-Disease-Pipeline.html

GLOBENEWSWIRE
01 Dec 2025

https://www.globenewswire.com/news-release/2025/11/24/3193434/37519/en/Akebia-Therapeutics-to-Present-at-the-Piper-Sandler-37th-Annual-Healthcare-Conference.html

GLOBENEWSWIRE
24 Nov 2025

https://www.globenewswire.com/news-release/2025/11/06/3183315/37519/en/Vafseo-vadadustat-Dialysis-Dependent-Patient-Post-Hoc-Data-Analysis-Composite-of-All-Cause-Mortality-and-Hospitalization-Outcomes-Statistically-More-Favorable-for-Patients-Receivin.html

GLOBENEWSWIRE
06 Nov 2025

https://www.globenewswire.com/news-release/2025/11/04/3180261/37519/en/Akebia-Therapeutics-to-Present-at-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
04 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179802/37519/en/Akebia-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
03 Nov 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty